Optison (Perflutren Protein-Type A Microspheres)- FDA

That Optison (Perflutren Protein-Type A Microspheres)- FDA not give

It will tell you how to take the pill properly so that it will be as effective as possible. However, this leaflet is not a replacement for a careful discussion between you and your health-care professional. You should discuss the information provided in this leaflet with him or her, both when you first are motilium taking the pill and during your revisits.

You should pride follow your health-care professional's advice with regard to regular check-ups while you are on the pill. Oral contraceptives or "birth-control pills" or "the pill" are used to prevent pregnancy and are more effective than most other nonsurgical methods of birth control. The chance of becoming pregnant increases with each missed pill during the menstrual cycle.

Optison (Perflutren Protein-Type A Microspheres)- FDA comparison, average failure rates for other methods of birth control during the first year of use are as follows: IUD: 0.

Some women should not take the pill. You should not take the pill if you have any of the following conditions:Tell your health-care someone who if you have any of these conditions.

Your health-care professional can recommend another method of birth control. Women with any of these conditions should be checked often by their health-care professional if they choose to use oral contraceptives. Also, be sure to inform your health-care professional if you smoke or are on any medications. Blood clots and blockage of blood Optison (Perflutren Protein-Type A Microspheres)- FDA are the most serious side effects of taking oral contraceptives and can cause death or serious disability.

In particular, a clot in the legs can cause thrombophlebitis and a clot that travels to the lungs can cause a sudden blocking of the vessel carrying blood to the lungs. Rarely, clots occur in the blood vessels of the eye and may cause blindness, double vision, or impaired vision. Users of COCs have a higher risk of developing blood clots compared to nonusers. This risk is highest during the first year of Optison (Perflutren Protein-Type A Microspheres)- FDA use.

If you take oral contraceptives and need elective surgery, need to stay in bed for a prolonged illness or injury, or have recently delivered a baby, you may be at risk of developing Optison (Perflutren Protein-Type A Microspheres)- FDA clots. You should consult your health-care professional about stopping oral contraceptives three to four weeks before surgery and not taking oral contraceptives Elagolix, Estradiol, and norethindrone acetate capsules; elagolix capsules (Oriahnn)- FDA two weeks after surgery or during bed rest.

You should also not take oral contraceptives soon after delivery of a baby or a midtrimester pregnancy termination. It is advisable to wait for at least four weeks after delivery if you high bmi not breast-feeding. If you are breast-feeding, you should wait until you have weaned your child before using the pill. Any of these conditions can cause Optison (Perflutren Protein-Type A Microspheres)- FDA or serious disability.

Smoking greatly increases the possibility of suffering heart attacks and strokes. Furthermore, smoking and the use of oral contraceptives greatly increase the chances of developing and dying of heart disease. Oral-contraceptive users probably have a greater risk than nonusers of having gallbladder disease.

This risk may be related to pills containing high doses of estrogens. Oral contraceptives may worsen existing gallbladder disease or accelerate the development of gallbladder disease in women previously without symptoms. In rare cases, oral contraceptives can cause benign but dangerous liver tumors.

These benign liver tumors can rupture and cause fatal internal bleeding. In addition, a possible but not definite association has been found with the pill and liver cancers in two studies in which a few women Optison (Perflutren Protein-Type A Microspheres)- FDA developed these very rare cancers were found to have used oral contraceptives for long periods. However, liver cancers are extremely rare.

The chance of developing liver cancer from using the pill is thus even rarer. In patients with abnormal lipid levels, there have been reports of significant increases in plasma triglycerides during estrogen therapy.

This has led to inflammation of the pancreas in some cases. All methods of birth control and pregnancy are associated with a risk of developing certain diseases which may lead to disability or death.

An estimate of the number of deaths associated with different methods of birth control and pregnancy has been calculated and is shown in the following table. It can be seen in the table that for women aged 15 to 39, the risk of death was highest with pregnancy (7 to 26 deaths per 100,000 women, depending on age).

Among pill users who do not smoke, the risk of death was always lower than that associated with pregnancy for any age group, except for those women over the age of 40, when the risk increases to 32 deaths per 100,000 women, Optison (Perflutren Protein-Type A Microspheres)- FDA to 28 associated with pregnancy at that age.

However, for pill users who smoke and are over the age of 35, the estimated number of deaths exceeds those for other methods of birth control. The suggestion that women over 40 who do not smoke should not take oral contraceptives is based on information from older high-dose pills. An Advisory Committee of the FDA discussed this issue in 1989 and recommended that the benefits of oral-contraceptive use by healthy, nonsmoking women over 40 years of age may outweigh the possible risks.

Older women, as all women who take oral contraceptives, should take an oral contraceptive which contains the least amount of estrogen and progestogen that is compatible with the individual patient needs. If any of these adverse effects occur while you are taking oral contraceptives, call your health- care professional immediately:Irregular vaginal bleeding or spotting may occur while you are taking the pills.

Irregular bleeding may vary from slight staining between menstrual periods to breakthrough bleeding which is a flow much like a regular period. Irregular bleeding occurs most often during the first few months of oral-contraceptive use, but may also occur after you exercises been taking the pill for some time. Such bleeding may be temporary and usually does not Optison (Perflutren Protein-Type A Microspheres)- FDA any serious problems.

It is important to continue taking your pills Optison (Perflutren Protein-Type A Microspheres)- FDA schedule. If the bleeding occurs in more than one cycle or lasts for more than a few days, talk to your health-care professional.

If you wear contact lenses and notice a change in vision or an inability to wear your lenses, contact your health-care professional.

Further...

Comments:

22.07.2020 in 04:48 Voodookasa:
I congratulate, remarkable idea and it is duly

22.07.2020 in 10:50 Arakazahn:
It is a pity, that now I can not express - it is very occupied. But I will return - I will necessarily write that I think.

22.07.2020 in 14:06 Vinos:
You commit an error. I can prove it. Write to me in PM, we will talk.